Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients
Descriptive Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients - An Observational Retrospective Study
Sponsor: Novo Nordisk A/S
A observational or N/A phase clinical study on Congenital Bleeding Disorder and Haemophilia A, this trial is actively recruiting participants. The trial is conducted by Novo Nordisk A/S and has accumulated 8 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting
-
Oct 2025 — Jan 2026 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting
▶ Show 3 earlier versions
-
May 2025 — Aug 2025 [monthly]
Recruiting
-
Feb 2025 — May 2025 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .